BRAK LABS Peptide research, plainly written

safety record

KPV: what has been measured about safety

The safety record for KPV, read as a record: what has been measured, what the two federal databases returned and why their silence measures the reporting, and the one animal finding that points the other way.

Last Reviewed Editorial policy Methodology

KPV is the last three amino acids of a hormone the body already makes, and its safety record is short enough to set out in full on one page. FDA reviewed both KPV free base and KPV acetate for the July 2026 advisory committee and recorded, category by category, what the nonclinical file holds: for acute toxicity, repeat-dose toxicity, genotoxicity, developmental and reproductive toxicity and carcinogenicity alike, the nominator submitted nothing and the agency's own search found nothing [25].

A complete absence of toxicology is not a set of reassuring results, and this page is written so the two never get mistaken for each other. A compound with a completed fourteen-day rodent toxicology study has a measurement behind it, whatever that measurement showed. KPV has the question.

What does exist is smaller and more specific than either camp usually reports: two federal databases that returned nothing and can say why, a chemistry finding about what the molecule turns into, and one animal result about the transporter KPV travels through that runs opposite to the way the compound is sold.

Not medical advice

This page reports what has been documented about a compound. It is not medical advice, not a diagnosis, not a dosing protocol, and not a recommendation to obtain or use anything described here. Talk to a licensed clinician about anything concerning your health. Read the full disclaimer.

Reviewed against editorial standards Updated

What this page reports, and what it does not

We report what has been documented. We do not prescribe what should be done.

Every sentence below reports what a named source measured or searched, in what system, and what it found. Where the answer is that nobody has looked, the page says which study would have looked and names the document recording that it was not done.

This page publishes no dose, no schedule, no route instruction and no list of people who should avoid anything. A list of who should not take a compound is a directions-for-use document, and it only makes sense if the reader is going to use the thing. What replaces it is a description of the compound and its record, written about the molecule rather than about the reader.

What has been measured

The toxicology record, item by item

FDA's Office of New Drug Products reviewed both KPV free base and KPV acetate for the July 2026 Pharmacy Compounding Advisory Committee, and the nonclinical section of that document is an enumeration of absences rather than of findings [25]. For each form the agency records that the nominator submitted no study and that FDA's own literature search identified none, across acute toxicity, repeat-dose toxicity, genotoxicity, developmental and reproductive toxicity, and carcinogenicity.

Those five categories are not a wish list. They are the standard preclinical package a molecule accumulates before anyone gives it to a person on purpose, and each one answers a different question: what a single large exposure does, what daily exposure does over weeks, whether the molecule damages DNA, what it does to a pregnancy and to the offspring, and whether lifetime exposure produces tumours. For KPV, none of the five has an answer in any species.

The longest anyone has administered KPV to an animal, in any published experiment on this compound, is the duration of a colitis model, and none of those experiments was designed to measure harm. They measured body weight recovery, histological inflammation, colonic myeloperoxidase and cytokine levels in a chemically injured rodent colon [7] [8] [9] [11] [13] [14]. An observation made in passing inside an experiment built for something else is not a toxicology result, and this page does not convert one into the other.

What the federal databases returned, and what a null return measures

FDA's Office of Surveillance and Epidemiology searched the FAERS adverse event database and the medical literature for KPV through 3 December 2025 and retrieved no adverse event reports and no literature cases [25]. That is the sentence most often quoted about this compound, and it is quoted without the half the agency attached to it.

The agency's own document states the limitation. There is no documented clinical exposure to KPV, and the compounding channel the material circulates through does not report adverse events to FDA. A null return from a surveillance system nobody reports into measures the reporting, not the compound. The same search would return nothing for a substance that harms everyone who takes it and nothing for a substance that harms no one, and it cannot tell the two apart.

So the honest reading is that nothing is known in either direction, and this site makes no claim about tolerability because no data exists that could establish one.

Immunogenicity and aggregation, both unassessed

FDA's review notes that peptides as short as two amino acids have been shown to aggregate, that aggregation is itself a risk factor for an immune reaction, and that neither property was assessed for KPV. Aggregation is worth a plain sentence because it is the mechanism behind the concern: peptide molecules can clump together into larger particles, and an immune system is more likely to react to a clump than to a single small molecule.

The agency's conclusion, in its own words: based on available information there is insufficient data to conclude that KPV (free base) or KPV acetate do not present these risks [25]. Read that carefully in both directions. It is not a finding that a problem exists, and it is not permission to assume one does not. It is a statement that the question was never put.

What is in the vial has not been described

FDA's reviewers concluded that both forms are not well characterized from the physical and chemical characterization perspective, on two grounds that apply to both: naming conventions that follow no INN, IUPAC or USAN standard, and the absence, from the public literature and from the nomination package alike, of substance-specific quality attributes including impurities, aggregates and microbiological tests [25].

That is an identity and quality finding rather than a harm finding, and it is the reason the agency's own reviewers proposed against listing. It also sets the ceiling on everything else on this page: a substance whose impurity profile has never been described cannot have its risks described either, because nobody can say what was in the material any given study used.

One measurement in that section is worth following to its source. FDA recorded the free base at 0.7 milligrams per millilitre of water, called that limited, and said it could not evaluate a proposed 0.1 percent cream or gel because the nominator supplied no formulation information. It recorded KPV acetate at 5 milligrams per millilitre and concluded that solubility and particle size would not be issues of concern for those same forms [25]. The free-base figure carries a footnote sourcing it to a peptide vendor's certificate of analysis, which is exactly the class of document the sourcing section of the main review is about.

What KPV turns into when it breaks down

One published account exists of what happens to KPV chemically. A 2015 stability-indicating HPLC assay put the peptide through acid, alkaline and oxidative stress in aqueous solution and in skin homogenate, and identified lysine-proline diketopiperazine as the major degradation product [16].

What that degradation product does has never been characterised, in any system. So the record holds an identification and nothing after it: the molecule that KPV becomes has a name and no biology. [In-vitro] [16]

The transporter finding, which runs the other way

KPV enters the lining of the gut through a transporter called PepT1, and the paper establishing that route reported a second result in the same experiments. Mice engineered to overexpress human PepT1 carried a larger tumour burden, knockout mice carried less, and human colorectal cancer biopsies showed increased PepT1 expression [10]. The transporter that carries KPV into the tissue it is sold to act on is the same transporter that paper associates with tumour promotion, and nobody has followed up on what the combination means.

Be exact about what that does and does not say. It is a finding about the transporter in a mouse model of colitis-associated cancer, not a finding about KPV causing anything, and the same paper reports a therapeutic benefit from delivering KPV through it. What it establishes is that the one delivery mechanism the literature has demonstrated for this compound sits inside a biology the same authors link to tumour growth, and that no study has since separated the two. [Animal] [10]

Liver, kidney and the organs nobody has looked at

Searches about this compound cluster on specific organs, and the answer is the same for every one of them, so it is worth giving that answer once and giving the reason with it.

Liver

No study in any species has measured a liver endpoint for KPV. The study type that would have is the repeat-dose toxicity study, which is where serum chemistry, organ weights and histopathology are collected as a matter of routine, and FDA records that no repeat-dose study of either form was submitted or found [25].

The rodent work that does exist measured the colon. Across the colitis studies the endpoints were body weight recovery, histological inflammatory infiltrate, colonic myeloperoxidase and cytokine levels [7] [8] [9] [11] [13] [14]. Serum alanine aminotransferase, bilirubin and liver histology appear in none of them, so there is no observation to report in either direction.

The comparison worth drawing is with a compound where the answer is different. Where a repeat-dose package exists, an agency can name the exact enzyme that moved, in which sex, at which exposure, and how long after treatment ended. For KPV there is no such sentence to write, and writing one anyway is the failure this page exists to avoid.

Kidney

The same answer, from the same absence. No published study of KPV in any species reports serum creatinine, urea, urinalysis or renal histology, because no study was designed to collect them and the repeat-dose study that would have is one of the five FDA records as missing [25].

Nothing in the surveillance record fills the gap either. The FAERS and literature searches through 3 December 2025 returned nothing at all, so they returned nothing renal, and the limitation on that null applies here exactly as it applies everywhere else on this page [25].

Skin, where most of the retail interest sits

Topical KPV is worth its own line because the most load-bearing measurement on the compound is a permeation result rather than a safety result. In a laboratory permeation cell using dermatomed human cadaver skin, passive diffusion of KPV fell below the assay limit of detection; microneedle pretreatment raised it to a measurable rate and iontophoresis raised it further [17].

That is a statement about whether the molecule crosses intact human skin on its own, and the answer measured there is that it does not. It says nothing about what KPV does once it is inside living skin with a circulation, and it is not a toxicology finding. It is included here because a compound that does not measurably cross a barrier and a compound that crosses it safely are two different situations, and only one of them has been measured. [In-vitro] [17]

What has not been characterised

Set out plainly, so the shape of the gap is visible rather than implied. Nothing is published on what a single large exposure does, what daily exposure does over weeks or months, whether the molecule affects DNA, what it does in pregnancy or to offspring, whether lifetime exposure produces tumours, whether the material aggregates, whether it provokes an immune response, what its impurity profile contains, or what its one identified degradation product does [25].

Nothing is published on the injected route in any species, which is the route the compound is most often sold for. Nothing is published on interaction with any other substance. And no human being has received KPV under a protocol anybody wrote down, so there is no clinical exposure record for a surveillance system to have captured.

Two things follow, and only two. This page cannot describe the risks of KPV, because the studies that would describe them do not exist. And nobody else can describe its safety either, from the same absence, whatever a product page says.

Our takeThe most common error made about this compound is reading two empty federal databases as a clean bill of health. FDA searched FAERS and the literature and found nothing, and FDA also wrote down why that finding cannot carry weight: there is no documented clinical exposure and the channel this material moves through does not report to the agency. An empty file drawer is evidence about the filing system.

Talk to a licensed clinician about anything concerning your health.

Frequently asked questions

Is KPV safe?

Nobody can answer that from published evidence, and this site will not answer it from anything else. FDA's 2026 review records that no acute, repeat-dose, genotoxicity, developmental and reproductive, or carcinogenicity study of KPV exists in any species, for either the free base or the acetate [25]. That is an absence of measurement rather than a measurement of absence, and the two get confused constantly.

Does KPV affect the liver or the kidneys?

Nothing published measures either. The study type that collects liver enzymes, kidney markers, organ weights and histology is the repeat-dose toxicity study, and FDA records that none was submitted or found for either form of KPV [25]. The rodent studies that do exist measured the colon: body weight, histological inflammation, myeloperoxidase and cytokines [7] [8] [9] [11] [13] [14]. So there is no liver or kidney observation to report in either direction.

Are there any reported side effects of KPV?

FDA searched the FAERS adverse event database and the medical literature through 3 December 2025 and retrieved no reports and no cases [25]. The agency attached its own limitation to that result and it travels with it: there is no documented clinical exposure to KPV, and the compounding channel it circulates through does not report adverse events to FDA. A null result from a system nobody reports into measures the reporting.

Does KPV cause cancer?

No study has tested it, and the carcinogenicity study that would is one FDA records as absent [25]. There is one finding in the neighbourhood and it deserves stating precisely: the paper establishing that KPV enters the gut lining through the PepT1 transporter also reported that mice overexpressing human PepT1 carried a larger tumour burden, that knockout mice carried less, and that human colorectal cancer biopsies showed increased PepT1 expression [10]. That is a result about the transporter in a mouse model, not about KPV causing tumours, and the same paper reports a therapeutic benefit from delivering KPV through it. Nobody has followed up on what the combination means.

Can KPV and GHK-Cu be used together?

No study has ever given the two together to anything, in any species, so there is no published record of the combination to report. Each compound's own record is thin in a different way, and each is set out where its sources are: KPV has no toxicology study of any kind [25], and what the GHK-Cu record holds is set out, with its sources, on the GHK-Cu safety record, linked under Safety records this page refers to at the foot of this page. Neither of those pages says anything about what the two do in combination, and a combination is a third thing rather than the sum of two.

Is KPV acetate safer than the free base?

Nothing published compares them on any safety measure. FDA reviewed both and reached the same conclusion for each on toxicology, surveillance and immunogenicity: no studies, no reports, no assessment [25]. The two do differ on one measured property, and it is a chemistry one rather than a safety one. FDA recorded the free base at 0.7 milligrams per millilitre of water and KPV acetate at 5 milligrams per millilitre, and it concluded that solubility and particle size would not be issues of concern for the acetate in a cream or gel while it could not evaluate the free base in the same forms at all [25].

What would change what this page says?

A published toxicology study in any species would, and it would be the first. So would a registered human trial, since there is none, or an adverse event report reaching a surveillance system this material actually reports into. A vendor's certificate of analysis would not: it describes one batch against the tests someone chose to run, and FDA's own review notes that no substance-specific impurity, aggregate or microbiological attributes have been published for this compound at all [25].

References

  1. Hiltz ME, Lipton JM. Antiinflammatory activity of a COOH-terminal fragment of the neuropeptide alpha-MSH. FASEB J. 1989. PMID 2550304
  2. Getting SJ, Schioth HB, Perretti M. Dissection of the anti-inflammatory effect of the core and C-terminal (KPV) alpha-melanocyte-stimulating hormone peptides. J Pharmacol Exp Ther. 2003. PMID 12750433 DOI 10.1124/jpet.103.051623
  3. Mandrika I, Muceniece R, Wikberg JE. Effects of melanocortin peptides on lipopolysaccharide/interferon-gamma-induced NF-kappaB DNA binding and nitric oxide production in macrophage-like RAW 264.7 cells: evidence for dual mechanisms of action. Biochem Pharmacol. 2001. PMID 11239505 DOI 10.1016/s0006-2952(00)00583-9
  4. Lyson K, Ceriani G, Takashima A, Catania A, Lipton JM. Binding of anti-inflammatory alpha-melanocyte-stimulating-hormone peptides and proinflammatory cytokines to receptors on melanoma cells. Neuroimmunomodulation. 1994. PMID 7489322 DOI 10.1159/000097145
  5. Elliott RJ, Szabo M, Wagner MJ, Kemp EH, MacNeil S, Haycock JW. alpha-Melanocyte-stimulating hormone, MSH 11-13 KPV and adrenocorticotropic hormone signalling in human keratinocyte cells. J Invest Dermatol. 2004. PMID 15102092 DOI 10.1111/j.0022-202X.2004.22404.x
  6. Land SC. Inhibition of cellular and systemic inflammation cues in human bronchial epithelial cells by melanocortin-related peptides: mechanism of KPV action and a role for MC3R agonists. Int J Physiol Pathophysiol Pharmacol. 2012. PMID 22837805
  7. Dalmasso G, Charrier-Hisamuddin L, Nguyen HT, Yan Y, Sitaraman S, Merlin D. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008. PMID 18061177 DOI 10.1053/j.gastro.2007.10.026
  8. Kannengiesser K, Maaser C, Heidemann J, Luegering A, Ross M, Brzoska T, Bohm M, Luger TA, Domschke W, Kucharzik T. Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Inflamm Bowel Dis. 2008. PMID 18092346 DOI 10.1002/ibd.20334
  9. Laroui H, Dalmasso G, Nguyen HT, Yan Y, Sitaraman SV, Merlin D. Drug-loaded nanoparticles targeted to the colon with polysaccharide hydrogel reduce colitis in a mouse model. Gastroenterology. 2010. PMID 19909746 DOI 10.1053/j.gastro.2009.11.003
  10. Viennois E, Ingersoll SA, Ayyadurai S, Zhao Y, Wang L, Zhang M, Han MK, Garg P, Xiao B, Merlin D. Critical role of PepT1 in promoting colitis-associated cancer and therapeutic benefits of the anti-inflammatory PepT1-mediated tripeptide KPV in a murine model. Cell Mol Gastroenterol Hepatol. 2016. PMID 27458604 DOI 10.1016/j.jcmgh.2016.01.006
  11. Xiao B, Xu Z, Viennois E, Zhang Y, Zhang Z, Zhang M, Han MK, Kang Y, Merlin D. Orally targeted delivery of tripeptide KPV via hyaluronic acid-functionalized nanoparticles efficiently alleviates ulcerative colitis. Mol Ther. 2017. PMID 28143741 DOI 10.1016/j.ymthe.2016.11.020
  12. Sun J, Xue P, Liu J, Huang L, Lin G, Ran K, Yang J, Lu C, Zhao YZ, Xu HL. Self-cross-linked hydrogel of cysteamine-grafted gamma-polyglutamic acid stabilized tripeptide KPV for alleviating TNBS-induced ulcerative colitis in rats. ACS Biomater Sci Eng. 2021. PMID 34547895 DOI 10.1021/acsbiomaterials.1c00792
  13. Zhao Y, Xue P, Lin G, Tong M, Yang J, Zhang Y, Ran K, Zhuge D, Yao Q, Xu H. A KPV-binding double-network hydrogel restores gut mucosal barrier in an inflamed colon. Acta Biomater. 2022. PMID 35245681 DOI 10.1016/j.actbio.2022.02.039
  14. Cheng J, Wu P, Li C, Han Y, Sun M, Dou Y, Chen S, Zhang J. Inflammation-triggered self-immolative conjugates enable oral peptide delivery by overcoming gastrointestinal barriers. Sci Adv. 2026. PMID 41533788 DOI 10.1126/sciadv.aea2989
  15. Bonfiglio V, Camillieri G, Avitabile T, Leggio GM, Drago F. Effects of the COOH-terminal tripeptide alpha-MSH(11-13) on corneal epithelial wound healing: role of nitric oxide. Exp Eye Res. 2006. PMID 16965771 DOI 10.1016/j.exer.2006.07.014
  16. Pawar KR, Mulabagal V, Smith F, Kolli CS, Rangari VK, Babu RJ. Stability-indicating HPLC assay for lysine-proline-valine (KPV) in aqueous solutions and skin homogenates. Biomed Chromatogr. 2015. PMID 25298219 DOI 10.1002/bmc.3347
  17. Pawar K, Kolli CS, Rangari VK, Babu RJ. Transdermal iontophoretic delivery of lysine-proline-valine (KPV) peptide across microporated human skin. J Pharm Sci. 2017. PMID 28343991 DOI 10.1016/j.xphs.2017.03.017
  18. Songok AC, Panta P, Doerrler WT, Macnaughtan MA, Taylor CM. Structural modification of the tripeptide KPV by reductive "glycoalkylation" of the lysine residue. PLoS One. 2018. PMID 29953505 DOI 10.1371/journal.pone.0199686
  19. Zhao Y, Huang L, Lin G, Tong M, Xie Y, Pan H, Shangguan J, Yao Q, Xu S, Xu H. Skin-adaptive film dressing with smart-release of growth factors accelerated diabetic wound healing. Int J Biol Macromol. 2022. PMID 36240893 DOI 10.1016/j.ijbiomac.2022.10.054
  20. Sung J, Ju SY, Park S, Jung WK, Je JY, Lee SJ. Lysine-Proline-Valine peptide mitigates fine dust-induced keratinocyte apoptosis and inflammation by regulating oxidative stress and modulating the MAPK/NF-kappaB pathway. Tissue Cell. 2025. PMID 40073467 DOI 10.1016/j.tice.2025.102837
  21. Brzoska T, Luger TA, Maaser C, Abels C, Bohm M. Alpha-melanocyte-stimulating hormone and related tripeptides: biochemistry, antiinflammatory and protective effects in vitro and in vivo, and future perspectives for the treatment of immune-mediated inflammatory diseases. Endocr Rev. 2008. PMID 18612139 DOI 10.1210/er.2007-0027
  22. Brzoska T, Bohm M, Lugering A, Loser K, Luger TA. Terminal signal: anti-inflammatory effects of alpha-melanocyte-stimulating hormone related peptides beyond the pharmacophore. Adv Exp Med Biol. 2010. PMID 21222263 DOI 10.1007/978-1-4419-6354-3_8
  23. Bohm M, Luger T. Are melanocortin peptides future therapeutics for cutaneous wound healing? Exp Dermatol. 2019. PMID 30661264 DOI 10.1111/exd.13887
  24. Gravina AG, Pellegrino R, Durante T, Palladino G, Imperio G, D'Amico G, Trotta MC, Dallio M, Romeo M, D'Amico M, Federico A. The melanocortin system in inflammatory bowel diseases: insights into its mechanisms and therapeutic potentials. Cells. 2023. PMID 37508552 DOI 10.3390/cells12141889
  25. US Food and Drug Administration. KPV-related bulk drug substances: briefing document for the Pharmacy Compounding Advisory Committee, review dated 12 May 2026. FDA advisory committee materials. 2026. Source document
  26. US Food and Drug Administration. Questions for PCAC regarding whether FDA should include certain bulk drug substances on the 503A Bulks List, Pharmacy Compounding Advisory Committee, 23 and 24 July 2026. Distributed as the final questions file; its own internal headers read QUESTIONS and DRAFT QUESTIONS (cont.). FDA advisory committee materials. 2026. Source document
  27. US Food and Drug Administration. Pharmacy Compounding Advisory Committee; notice of meeting; establishment of a public docket; request for comments. Docket No. FDA-2025-N-6895. Federal Register, document 2026-07361. 2026. Source document
  28. World Anti-Doping Agency. The 2026 Prohibited List, international standard, effective 1 January 2026. WADA. 2026. Source document
  29. Sun MC, Xu XL, Du Y, Lou XF, Wang W, You YC, Liu D, Jin FY, Qi J, Zhu MX, Zhu LW, Wang J, Du YZ. Biomimetic Melanosomes Promote Orientation-Selective Delivery and Melanocyte Pigmentation in the H2O2-Induced Vitiligo Mouse Model. ACS Nano. 2021. PMID 34662120 DOI 10.1021/acsnano.1c05321
  30. US Department of Defense, Operation Supplement Safety. Ingredient and substance index, and the DoD prohibited dietary supplement ingredients list. Checked for a KPV entry on 2 August 2026 and rechecked 8 August 2026: KPV has no entry and no article. BPC-157 has both, and its entry reads that BPC-157 is on the DoD Prohibited Dietary Supplement Ingredients list, with a status label of Prohibited. OPSS, Uniformed Services University. 2026. Source document
  31. Cutuli M, Cristiani S, Lipton JM, Catania A. Antimicrobial effects of alpha-MSH peptides. J Leukoc Biol. 2000. PMID 10670585 DOI 10.1002/jlb.67.2.233
  32. Böhm M, Apel M, Sugawara K, Brehler R, Jurk K, Luger TA, Haas H, Paus R, Eiz-Vesper B, Walls AF, Ponimaskin E, Gehring M, Kapp A, Raap U. Modulation of basophil activity: a novel function of the neuropeptide alpha-melanocyte-stimulating hormone. J Allergy Clin Immunol. 2012. PMID 22178636 DOI 10.1016/j.jaci.2011.11.012